chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Day 1: Hives and welts started on lower buttocks down thighs. Day 2: diffuse rash on stomach and arms. Pt took Allegra Q12 with hydrocortisone cream topical, also started medrol pack- symptoms improved. Completed medrol on 1/12/21. On 1/13/21 hives started appearing. 1/14/21 generalized hives again.
R29.810 LEFT FACIAL MUSCLE WEAKNESS 4/14/2023 LEFT FACIAL MUSCLE WEAKNESS
Patient came in today and reported an anaphylactic like reaction to the first shingles shot -- said her left side of face was numb and swollen including the areas around her eyes, nose and mouth. She  said she had chills and chattering teeth and some tingling around the mouth and nose. Also reported a low grade fever. Her MD has all the information on her reaction.
3-4 days p/vax pt c/o severe joint pain in all fingers x 7 days; took APAP; did not report sx until seen 14JUL92 to discuss 2nd vax;
1) Area that was vaccinated became red. 2) Patient experienced heart palpitations & high pulse, went to E.R... was placed on potassium CL.
Right thigh area a little bit swollen and tender to touch.  Very light redness to area.
Suffered an auto immune reaction from her second dose; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), . The reporter is the patient.  A female patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1), for COVID-19 immunization. The following information was reported: AUTOIMMUNE DISORDER (medically significant), outcome "unknown", described as "Suffered an auto immune reaction from her second dose". The event "suffered an auto immune reaction from her second dose" required physician office visit. The patient underwent the following laboratory tests and procedures: Immunoglobulins: 85 or 85.9. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
This spontaneous report was received from a healthcare worker concerning unspecified number of patients of unknown age and gender. No concurrent conditions or medical history were reported. On an unknown date, unspecified number of patients were vaccinated with improperly stored doses of M-M-R II (L006545 Expiration date: 16-NOV-2017 and L012838 Expiration date: 10-MAR-2018). No adverse effect reported. No Product Quality Complaint (PQC) was involved. This is one of several reports received from the same source. Additional information has been requested.
Localizing swelling, redness Approx. area 3.5 inches width x 2.25 length. Warm to touch. Pt. reported itching & scratching @ site. Tx with ice, Keflex 250mg/ml PO 10ml x 10 days + Hydroxyzine 5ml PO PRN 10 mg/ml
Five days after the vaccine employee experienced diarrhea,  followed by weakness in her lower extremities,  She is currently having intermittent cramping in her lower extremities and was prescribed Flexeril and B12 complex
Left arm from shoulder to elbow-red, swollen, hot to touch with several blisters in this area.  Complained of pain and tenderness at this site. MD Dx as cellulitis.
Second dose was given 23 days out from the first dose, no adverse event or allergic reaction
Pain in the site of administration for 3 days. Swelling of the lymph node.
(R) arm weakness & Pain S/P administration - probable iatrogenio Axillary Neuropathy.
Pt recv vax on 12/15/99; 30 min post vax pt exp tingling in fingers, diaphoresis, light headed; EMS called on pt car phone; dx=possible hyperventilation
Pt had a vasovagal episode and remained in clinice for 30 min observation.
D1 fever 103, headache, stomach ache, lethargy, rash started on back - multiple red papules D2 rash spread to proximal upper arms, back of neck, seen on ofc and dx possible varicella vs insect bite. D3 phone to mom - lesions on back crusty, oozing clear liq looked like tear drops before breaking, vomiting.
COPD exacerbation; wheeze; This spontaneous case was reported by a consumer and describes the occurrence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD exacerbation) and WHEEZING (wheeze) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037B21A) for COVID-19 vaccination.     The patient's past medical history included COPD and Lung scarring. Concomitant products included DOXEPIN HYDROCHLORIDE (ADAPIN), TIOTROPIUM BROMIDE MONOHYDRATE (SPIRIVA), FAMOTIDINE (PEPCID AC) and EZETIMIBE (ZETIA) for an unknown indication.    On 10-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Apr-2021, the patient experienced CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD exacerbation) (seriousness criterion hospitalization) and WHEEZING (wheeze) (seriousness criterion hospitalization). The patient was hospitalized on 10-Apr-2021 due to CHRONIC OBSTRUCTIVE PULMONARY DISEASE. At the time of the report, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD exacerbation) outcome was unknown and WHEEZING (wheeze) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication included an Inhaler. Treatment information included steroids, nebulizer treatments and oxygen.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
pt recvd vax; pt had football shaped rash around inject site w/ 3 or 4 blisters on rash;
Vaccine breakthrough, symptomatic.   Inpatient admit 9/12-9/16.
Information has been received from a pharmacist referring to a 67 year old female patient. The pertinent medical history and concomitant therapy were not reported. On 25-AUG-2016, the patient was vaccinated with a dose of ZOSTAVAX, "subcutaneously in the back of her arm" (lot#, expiration date and dose were unspecified). Subsequently, the patient developed a rash at the injection site. No treatment was given for the event and no lab diagnostics studies performed. The outcome of event was reported as not recovered/not resolved. Additional information has been requested.
AFTER THE FIRST SHOT ABOUT 10 DAYS LATER MY RIGHT KNEE AND RIGHT HIP (BOTH HAVE BEEN REPLACED ) WERE REALLY HURTING ME AND I THOUGHT I DID SOMETHING TO  HURT IT.  AFTER THE SECOND SHOT ON 3/21/2021 I GOT SHINGLES ON 2 DAYS AFTER THE SHOT.
Shingles; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (Shingles) in a 47-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     The patient's past medical history included No adverse event (The patient's medical history was not provided.  ).    On 18-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Feb-2021, the patient experienced HERPES ZOSTER (Shingles). At the time of the report, HERPES ZOSTER (Shingles) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.    Treatment for the event included antiviral medication.      Reporter did not allow further contact
THROMBOSIS; Dizziness; Pass Out; Weakness in the all side of the body; This spontaneous report received from a patient. The patient's height, and weight were not reported. The patient's concurrent conditions included sea food allergy, and other pre-existing medical conditions included the patient did not had any other illness at the time of vaccination and to one month prior and chronic or long standing health condition. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on 02-APR-2021 11:25 for prophylactic vaccination. The batch number was not reported. As per procedure, no follow-up will be requested for this case. Concomitant medications included metformin for drug used for unknown indication.  On an unspecified date, the subject experienced thrombosis, dizziness, pass out, and weakness in the all side of the body, and was hospitalized (date unspecified). Laboratory data (dates unspecified) included: X-ray (NR: not provided) heart, head and lungs. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from thrombosis, dizziness, pass out, and weakness in the all side of the body. This report was serious (Hospitalization Caused / Prolonged, and Life Threatening).; Sender's Comments: V0: This is a report of a patient,  who was noted to have thrombosis on unspecified time after receiving the covid-19 vaccine ad26.cov.2.  Patient's height and weight were not reported. Patient medical history was not reported. Concomitant medications included metformin for unknown indication. Patient is allergic to seafoods.  On an unspecified date, the subject experienced dizziness and passed out. She also had weakness on the left side of the body. Patient was noted to have thrombosis. Patient was hospitalized, where laboratory and diagnostic tests were done. Results were not reported.  The information provided precludes a meaningful medical assessment. Additional information requested.
This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 76-year-old male patient who received SHINGRIX for prophylaxis. On 18th August 2018, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. On 18th August 2018, less than a day after receiving SHINGRIX, the patient experienced injection site pain. On 18th August 2018, the outcome of the injection site pain was recovered/resolved. It was unknown if the reporter considered the injection site pain to be related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX in the left arm. The patient received the vaccine between 4:00 to 5:00 PM. The wife of the patient reported that the patient (her husband) received the SHINGRIX vaccine and he experienced soreness at the injection site. The soreness resolved and was only temporary on the day of his vaccination. The patient had denied permission to contact their physician.
very flushed; perspiring; Feeling hot; Red face; chills; This is a spontaneous report from a contactable pharmacist reporting for herself. A 43-year-old female patient received the 2nd dose of bnt162b2 (BNT162B2, Manufacture Pfizer-BioNTech, lot# EL3249), via an unspecified route of administration, on 24Jan2021 at 14:30, at single dose, for COVID-19 immunisation. Medical history included endometriosis and migraine. The patient was not diagnosed with COVID-19 prior to vaccination. Concomitant medications included ibuprofen (MOTRIN) and unspecified oral contraceptives. Previously the patient received the 1st dose of bnt162b2 (BNT162B2, Manufacturer Pfizer-BioNTech, lot# EL1284), on 04Jan2021 at 01:00 PM, in left arm, for COVID-19 immunisation. The patient experienced very flushed, perspiring, feeling hot, red face and chills all on 24Jan2021 at 15:00 with outcome of recovered after about 1 hour. Since the vaccination the patient has not been tested for COVID-19.
Information has been received from a female patient of unknown age concerning herself. No relevant medical history or concurrent conditions were reported. On 09-MAY-2015 the patient was vaccinated with GARDASIL (lot#, expiration date, dose and route not reported) (Exposure during pregnancy). On 06-JUN-2015, the patient was 5 weeks pregnant with Last Menstrual Period (LMP) of 01-MAY-2015 and Estimated Date of Delivery (EDD) of 05-FEB-2016. Additional information has been requested.
On the evening after receiving the vaccination the patient became febrile (101.4), development weakness, chills, sweats, and heart palpitations. She did not go to ER, took tylenol (x 3) and attempted to "sleep it off". These symptoms continued to occur daily (less intensity each day). Seen again in clinic on 7/29/19. Pt slightly improved but concerned about reaction. Provided patient with prednisone burst and encouraged to follow up as needed.
Afternoon after vaccine, upper arm tender reddened. 24 hours later, arm reddened, temp 101.2; seen in Emergency Dept 3/22/07 at 6:30 AM.  Dx cellulitis and given Keflex 500mg BID.  Did not improve; again seen in Emergency Dept 3/24/07 1:00 AM.  Admitted to hospital with increased pain and swelling. Given IV Ancef, Benadryl and Prednisone. Discharged 3/25/07 at 11:00 AM.  06/04/2007 MR received for o/n hospitalization for reaction to DTaP vax. Swelling and pain were noted in the area of the injection 2 days after receipt.  Seen in ER on 3/22/2007 and started on Keflex.  Returned to ER after pain and swelling were increasing despite tx. Txd with IV antibiotics and prednisone.  PE: WNL except thickening and swelling of subcutaneous tissues of the right deltoid.  Tenderness, warmth, and erythema noted. Assessment:  ?Cellulitis. ? allergic reaction.
Had vaccine 2d ago. Felt some local pain in muscle after 6 hrs then noted redness/swelling yesterday at site and below 18 1/2 x 12 cm. Edematous dependent with biceps and no induration or firmness. Denies pain at time of examination. Full range of arm no neurological or circulation deficits. Denies nausea, headache, diarrhea. Cool pack, or TYLENOL and prn antihistamine if needed. Return ASAP prn.
pt recvd vax & sometime p/vax had constipation, pain in rt side, fatty lobe in liver, back pain; pt was seen by MD;
Breakthrough case: On 09/07/2021, I developed these symptoms; congestion in the head, fever, coughing, and I was lethargic.   One day I felt good and the next day I would feel wiped out.
Back side of (R) upper arm swollen, red, warm to touch, tender to touch in an area approx. golf ball sized where received varicella vaccine on 5/24/11 in the AM.
This case was reported by a consumer via call center representative and described the occurrence of itchy rash in a 79-year-old male patient who received SHINGRIX for prophylaxis. Previously administered products included SHINGRIX with an associated reaction of headache (on 20th March 2018, vaccinated with the 1st dose). Concurrent medical conditions included rheumatoid arthritis, prostate cancer, brachytherapy (prostate cancer radioactive seed implantation therapy) and radiotherapy (for treating prostate cancer for 28 days, ending on 3rd August 2018). On 14th September 2018, the patient received the 2nd dose of SHINGRIX. On an unknown date, 2 days after receiving SHINGRIX, the patient experienced itchy rash. The patient was treated with cortisone acetate, prednisone and BENADRYL. On an unknown date, the outcome of the itchy rash was not recovered/not resolved. It was unknown if the reporter considered the itchy rash to be related to SHINGRIX. Additional information was reported as follows: On Friday, the patient was vaccinated with the 2nd dose of SHINGRIX in the right deltoid. The patient did not experience any symptoms within the first 24 hours after vaccination with SHINGRIX. The patient stated that he felt normal till Saturday night, however after Saturday midnight the patient experienced rash on his lower back which spread to his groan, neck and under his arm and it itched badly. On 16th September 2018, the patient went to the urgent care and was given a cortisone, a prednisone shot and BENADRYL. On Monday, 17th September 2018, the rash experienced by the patient was still the same and existed up to the back of his neck till the time of reporting. The patient's wife might take him to his primary doctor on the day of reporting. The physician contact details were provided.
Patient received 4 doses of Rabavert  and  Rabies Immunoglobin for an exposure to a bat and bat bite. According to patient, pain in leg, tingling/numbness in toes, fatigue, lightheadedness, dizziness, nausea, racing heart beat after each vaccination and hoarseness.
Rash and red welt at the injection site that is round and two inches but 2 inches.
Tinnitus was exacerbated after the first dose, got tinnitus in left ear/Had tinnitus generally but has been exacerbated after the vaccine/Still pretty intense; This spontaneous case was reported by a consumer and describes the occurrence of TINNITUS (Tinnitus was exacerbated after the first dose, got tinnitus in left ear/Had tinnitus generally but has been exacerbated after the vaccine/Still pretty intense) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 008B21-2A and 045B21A) for COVID-19 vaccination.     Concurrent medical conditions included Tinnitus.   On 26-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 29-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced TINNITUS (Tinnitus was exacerbated after the first dose, got tinnitus in left ear/Had tinnitus generally but has been exacerbated after the vaccine/Still pretty intense). At the time of the report, TINNITUS (Tinnitus was exacerbated after the first dose, got tinnitus in left ear/Had tinnitus generally but has been exacerbated after the vaccine/Still pretty intense) had not resolved.            No concomitant products were reported.  The patient reported that about three days after the first dose of the vaccine her tinnitus got worse only in left ear. She had tinnitus generally but has been exacerbated after the vaccine. She saw health care professional and was told this should go away after three months and it had not, it was still pretty intense.  No treatment information provided.
Baby born at 35 weeks gestation without complications at 2 months.  Shots, baby given Tylenol before shots and had 103 degree fever (rectally) for 24 hours and was "extremely" fussy.  At 4 months, baby got Tylenol after shots.  This time he had 103 degree temperature and persistent crying for 48 hours.  Both at 2 and 4 months, baby had large, warm, red injection sites.
p/vax pt exp oblong white welt approx 4cm longx1/2cm wide c/redness around edges;pt not allergic to eggs; applied cold compresses; rxn to MMR
8 hours after receiving vaccine, pt developed fever up to 101F x 2 weeks.
On 2/18/00, developed redness and swelling from shoulders to elbow, water blisters appeared on site of DTAP. Was seen in ER and placed on antibiotics, Benadryl and Motrin. Seen 2/21/00, redness still slight and water blisters are healing.
pt recvd vax during 4th wk of pregnancy; f/u info revealed that pt underwent an elective abortion; No further details were provided;
From telephone contact with reporting nurse it was stated that a 14 month old male patient received an IPOL vaccination on 5/23/01. The patient developed generalized urticaria 48 hours after vaccination, which persisted for 3 weeks and then resolved.
Sudden Bilateral Hearing Lost; This case was reported by a nurse via call center representative and described the occurrence of hearing loss bilateral in a 68-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 13th August 2019, the patient received the 1st dose of Shingrix. On an unknown date, less than 3 months after receiving Shingrix, the patient experienced hearing loss bilateral (serious criteria GSK medically significant). On an unknown date, the outcome of the hearing loss bilateral was unknown.   It was unknown if the reporter considered the hearing loss bilateral to be related to Shingrix.  Additional details were provided as follows: This case was reported by the license practice nurse. The patient experienced sudden bilateral hearing lost. The reporter was unable to provide full details.  The reporter would like follow up at earliest convenience and gave consent
07SEP89 pt vax w/hepta B; devel flu-like sx w/n/v, weakness, sweats & loss of taste.  21OCT89 vax 2nd hepta B & sx reoccurred.  01NOV89 devel elevated SGOT, arthralgia, & myalgia. Tx w/Compazine.
Varicella - Information has been received concerning a 33 month old Caucasian male who on 08 Sep 1998 was vaccinated with one dose of varicella virus vaccine live.  Concomitant therapy included vitamins.  On 04 May 2000 the patient experienced chickenpox with at least 300 lesions.  He also experienced pustules.  The rash worsened.  The diagnosis was made by a physician on 08 May 2000.  On 09 May 2000 a VZV culture revealed no viurs, however, the physician felt it was chickenpox.  Three emergency room physician visits were required.  The patient was administered cetiritine dihydrochloride (Zyrtec).  The patient recovered on 12 May 2000.
I didn't have any adverse affects until 5 days after I received the vaccination. Early in the afternoon on Wednesday 1/20 I noticed that my lymph nodes in the armpit of my left arm and on the left side of my neck were swollen and sore. This worsened as the day went on. I also noticed a pimple had formed and came to a head in the exact spot of where the needle stick had been. It "popped" that day and a small amount material came out. My lymph nodes have remained sore and swollen since 1/20. On the 7th day after (1/22) I noticed a couple of smaller, dime sized red blotches/rash on my left shoulder and left side of my neck. I also noticed that the injection site on my left shoulder was sore, swollen and hot to touch. On the 8th day (1/23) I noticed that there were more of these dime sized red blotches/rash across both shoulders, my back and a small area in the center of my chest.  It continues to be like that as of today (1/25). On the 9th day, (1/24) starting just after noon, I began to feel poorly. Achy and just generally not very good. I had a few bouts of diarrhea throughout the afternoon. I also had a pretty strong headache when I awoke on the morning of the 24th. Today, (1/25) I awoke again with a headache although it was not as sore as yesterday. I don't feel great today, but I do feel better than I did yesterday. The rash looks the same and my lymph nodes seem to be slightly less swollen and less sore.
Allergy; This spontaneous case was received on 09-Mar-2022 from other non-health care professional (consumer) via Agency (reference number: NVSC2022US051254_NS) and concerned a female patient. At the time of this report, the patient was 67-year-old.   The patient's medical history and concomitant medications were not reported.  On an unspecified date, the patient was vaccinated with influenza virus vaccine polyvalent (brand not specified; dose, route of administration, anatomical location and indication: not reported). The batch number was not reported.  On an unspecified date, an unknown amount of time after receiving influenza virus vaccine polyvalent, the patient experienced allergy.   The outcome of the event was not reported.  The reporter did not provide a causality assessment.  The case was assessed as non-serious.  Company comment: The event of 'allergy' is assessed as unassessable to influenza virus vaccine polyvalent due to insufficient information provided.; Sender's Comments: The event of 'allergy' is assessed as unassessable to influenza virus vaccine polyvalent due to insufficient information provided.
On 10/17/19, child jerked upon administration of varicella vaccine, causing a scratch to his right arm. On 10/17/19, the mother took the child to Hospital ER due to fever and swelling of the right arm.
Recvd Td 12Feb91-became sore, itching, red @ inject site. Rash appeared /p itching began, area became swollen-experienced malaise, pt applied alcohol to area-remains tender to touch & on movement of arm
Pt states began itching all over on 7/23/03 but did not tell mom. Small red raised rash noted on trunk and thighs. To Dr today per mom.
6 wks after MMR developed acute idiopathic thrombocytopenia. Diagnosed and treated by doctor.